Project proposals will be considered that leverage modern technologies to create new breakthrough solutions to be more prepared for pandemic outbreaks or work towards existing solutions that could help to fight emerging viral infections.
Deadline: August 31, 2020
The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Congressionally directed FY20 PRMRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.
Deadline: August 13, 2020
On January 30th, 2020, the WHO declared the recent outbreak of coronavirus disease 2019 (COVID-19), a public health emergency of international concern. It declared that there is an urgent need to improve our understanding of the newly identified virus and its possible future evolution as well as to contain the spread; to develop precise diagnostics and treatment, and to improve the public health response and patient care.
The SLS and the SwissFEL provide unique characterisation techniques to efficiently and promptly support these needs. PSI are opening a “PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the virus and/or to improve the clinical or public health response and patient care. This “PRIORITY COVID-19 Call” is explicitly for projects requiring a rapid access to beamtime within the next months. For other projects we are referring to our regular calls.
Deadline: September 9, 2020
In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
Contracts Management & Acquisition (CMA)on behalf of the Office of Biomedical Advanced Research and Development Authority (BARDA) solicits proposals for the advanced research and development of medical countermeasures (MCM) for chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.
Deadlines: A Quad Chart and White Paper may be submitted on any day during the open period of the BAA. Submission deadlines are as follows:
Defense Logistics Agency (DLA) Troop Support Clothing & Textiles Directorate is conducting market research to determine industry capabilities for providing Personal Protective Equipment (PPE) against viral contamination, specifically COVID-19. This is a Request for Information only and not a solicitation for award.
Deadline: Initial responses are requested by 5:00 PM, Tuesday, 24 March 2020. However, DLA will accept any and all responses received after this date and time for any ongoing requirements.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
Please read the full program announcement before preparing your internal application.
An Institution may submit one proposal.
If you are interested in submitting for this program, you must first submit an internal application to limsub@uga.eduaccording to the required instructions below.
Limited Submission announcements often generate multiple competing proposals. UGA reviewers judge proposals as they would in any peer review process, so PIs are urged to put their best foot forward. Along with typical criteria, reviewers will evaluate internal proposals based on their fit with the sponsor’s articulated goals and criteria.
The above internal application materials should be submitted via email as a single .PDF file to limsub@uga.edu by the internal deadline listed above.
Please submit questions regarding the internal competition to limsub@uga.edu.
For questions directly related to this program, please contact the following program officers:
Gang Dong, MD, PhD
Telephone: 240-627-3508
Email: gdong@niaid.nih.gov
View our calendar for all Current and Closed Limited Submissions.
Subscribe to our listerv to receive weekly internal competition announcements.
What is a Limited Submission?
REAC/TS is an Oak Ridge Institute for Science and Education facility with the mission to strengthen the medical response to radiological and nuclear incidents. REAC/TS has recently partnered with NASA to provide specialized knowledge for the medical community and emergency planners in the area around the upcoming Mars Rover Launch. ORISE is hosting a research-based challenge for undergraduate students to research a partner supporting NASA’s upcoming Mars 2020 Launch, learn about the partner’s capabilities, and discuss why that partner is necessary for the mission. Your research could win you a $5,000 scholarship!
Deadline: March 31, 2020
Ginko is offering $25M of no-cost foundry work towards projects that can use Ginkgo’s platform to accelerate development of point of care diagnostics, vaccines, or therapeutics. If you are currently a company or academic lab that is developing a diagnostic, drug, or vaccine and are interested in leveraging Ginkgo’s infrastructure at no cost please email us at covid-response@ginkgobioworks.com.
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Common Fund R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:
To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in cryoelectron microscopy (cryoEM) and cryoelectron tomography (cryoET) for structural and cell biology research.
Deadlines:
